DE MERCANTI, STEFANIA FEDERICA
DE MERCANTI, STEFANIA FEDERICA
SCIENZE CLINICHE E BIOLOGICHE
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome
2009-01-01 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
2017-01-01 Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View
2019-01-01 Maglione, Alessandro; Rolla, Simona; Mercanti, Stefania Federica De; Cutrupi, Santina; Clerico, Marinella
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
2016-01-01 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
ALS patients and caregivers communication preferences and information seeking behaviour
2008-01-01 CHIÒ A; MONTUSCHI A; CAMMAROSANO S; DE MERCANTI S; CAVALLO E; ILARDI A; GHIGLIONE P; MUTANI R; CALVO A.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study
2014-01-01 A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study
2015-01-01 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
2020-01-01 De Mercanti S.F.; Gned D.; Matta M.; Iudicello M.; Franchin E.; Clerico M.
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient
2015-01-01 De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L
Atypical presentation of superficial sclerosis successfully treated with iron chelation
2013-01-01 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study
2015-01-01 Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study
2019-01-01 Artusi, Carlo Alberto; Bortolani, Sara; Merola, Aristide; Zibetti, Maurizio; Busso, Marco; De Mercanti, Stefania; Arnoffi, Paolo; Martinetto, Simone; Gaidolfi, Elena; Veltri, Andrea; Barbero, Pierangelo; Lopiano, Leonardo
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis?
2010-01-01 Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
2021-01-01 De Mercanti S.F.; Vercellino M.; Bosa C.; Alteno A.; Schillaci V.; Clerico M.; Cavalla P.
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation
2017-01-01 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report
2016-01-01 De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome | 2009 | Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli | |
| Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab | 2017 | Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T | |
| The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View | 2019 | Maglione, Alessandro; Rolla, Simona; Mercanti, Stefania Federica De; Cutrupi, Santina; Clerico, Marinella | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months | 2016 | De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| ALS patients and caregivers communication preferences and information seeking behaviour | 2008 | CHIÒ A; MONTUSCHI A; CAMMAROSANO S; DE MERCANTI S; CAVALLO E; ILARDI A; GHIGLIONE P; MUTANI R; CALVO A. | |
| Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
| Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study | 2014 | A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register | |
| Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study | 2015 | Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A | |
| Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question | 2020 | De Mercanti S.F.; Gned D.; Matta M.; Iudicello M.; Franchin E.; Clerico M. | |
| Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient | 2015 | De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L | |
| Atypical presentation of superficial sclerosis successfully treated with iron chelation | 2013 | De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L | |
| Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study | 2015 | Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L | |
| Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study | 2019 | Artusi, Carlo Alberto; Bortolani, Sara; Merola, Aristide; Zibetti, Maurizio; Busso, Marco; De Mercanti, Stefania; Arnoffi, Paolo; Martinetto, Simone; Gaidolfi, Elena; Veltri, Andrea; Barbero, Pierangelo; Lopiano, Leonardo | |
| can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? | 2010 | Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli | |
| Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series | 2021 | De Mercanti S.F.; Vercellino M.; Bosa C.; Alteno A.; Schillaci V.; Clerico M.; Cavalla P. | |
| Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation | 2017 | Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S. | |
| Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report | 2016 | De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M |